Adial Pharmaceuticals, Inc. (ADIL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Adial Pharmaceuticals, Inc. (ADIL) Healthcare & Pipeline Overview

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in therapeutics for addiction, primarily alcohol use disorder, with its lead product AD04 undergoing Phase III trials, positioning it within the competitive biotechnology sector focused on innovative addiction treatments.

What Is the Investment Thesis for ADIL?

Adial Pharmaceuticals' investment thesis centers on the successful development and commercialization of AD04 for alcohol use disorder. The ongoing Phase III clinical trial results will be a critical value driver. Positive outcomes could lead to regulatory approval and subsequent market entry, potentially capturing a significant share of the AUD treatment market. The company's focus on non-opioid pain reduction also presents a growth opportunity, although it is in earlier stages of development. Key risks include clinical trial failures, regulatory hurdles, and the need for additional funding to support ongoing research and development activities. The company's small size and limited resources also pose challenges in a competitive biotechnology landscape.

Based on FMP financials and quantitative analysis

ADIL Key Highlights

AD04 is currently in Phase III clinical trials for the treatment of alcohol use disorder (AUD).

• Adial Pharmaceuticals is also developing drug candidates for non-opioid pain reduction.
• The company was founded in 2010 and is based in Charlottesville, Virginia.
• Adial Pharmaceuticals has a market capitalization of $0.00B.
• The company employs 5 individuals.

Who Are ADIL's Competitors?

ADIL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ADIL's Key Strengths?

Lead product (AD04) in Phase III clinical trials.

• Focus on a significant unmet medical need (AUD).
• Potential for non-opioid pain reduction therapies.
• Experienced management team.

What Are ADIL's Weaknesses?

Limited financial resources.

• Small number of employees.
• Reliance on the success of AD04.
• High risk associated with clinical-stage drug development.

What Could Drive ADIL Stock Higher?

Announcement of Phase III clinical trial results for AD04.

• Potential regulatory submission for AD04 approval.
• Development of drug candidates for non-opioid pain reduction.

What Are the Key Risks for ADIL?

Financial-distress signal — its Altman Z-Score of -12.39 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure of Phase III clinical trials for AD04.
• Regulatory rejection of AD04.
• Competition from other companies developing AUD treatments.
• Need for additional funding to support research and development.

What Are the Growth Opportunities for ADIL?

• Successful completion of Phase III clinical trials for AD04 represents a significant growth opportunity. Positive trial results would pave the way for regulatory approval and commercialization, potentially capturing a substantial share of the alcohol use disorder (AUD) treatment market. The global market for AUD treatments is estimated to be in the billions of dollars, offering significant revenue potential for Adial Pharmaceuticals. The timeline for this growth opportunity is dependent on the successful completion of the trials and subsequent regulatory review, with potential market entry within the next 2-3 years.
• Development of drug candidates for non-opioid pain reduction presents another growth avenue for Adial Pharmaceuticals. The opioid crisis has created a significant need for alternative pain management solutions, and Adial's research in this area could lead to the development of novel therapies with a large market potential. The market for non-opioid pain relievers is projected to grow significantly in the coming years, driven by increasing awareness of the risks associated with opioid use. The timeline for this growth opportunity is longer-term, as these drug candidates are in earlier stages of development.
• Strategic partnerships with larger pharmaceutical companies could accelerate the development and commercialization of Adial's drug candidates. Collaborations with established players in the pharmaceutical industry could provide access to funding, expertise, and distribution networks, enhancing Adial's ability to bring its therapies to market. The potential for partnerships exists across both the addiction treatment and pain management areas, offering multiple avenues for growth. The timeline for this opportunity is dependent on Adial's ability to attract and secure strategic alliances.
• Expansion into new geographic markets represents a potential growth opportunity for Adial Pharmaceuticals. Initially focusing on the US market, the company could explore opportunities to expand into Europe and other regions with a high prevalence of alcohol use disorder. The global market for AUD treatments is substantial, and expanding into new geographic markets could significantly increase Adial's revenue potential. The timeline for this growth opportunity is dependent on regulatory approvals and market access in each region.
• The application of AD04 to other addiction-related disorders beyond alcohol use disorder could unlock further growth opportunities. The underlying mechanism of action of AD04, as a selective serotonin-3 antagonist, may have therapeutic potential in other addiction areas, such as opioid or nicotine addiction. Exploring these potential applications could broaden the market for AD04 and increase its overall value. The timeline for this growth opportunity is dependent on further research and clinical trials to evaluate the efficacy of AD04 in these other addiction areas.

What Threats Does ADIL Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from existing and emerging AUD treatments.
• Need for additional funding.

What Are ADIL's Competitive Advantages?

• Patent protection for AD04 and other drug candidates.
• Proprietary knowledge and expertise in serotonin-3 antagonist mechanisms.
• Clinical trial data demonstrating efficacy and safety.
• Potential first-mover advantage in the AUD treatment market with AD04.

What Does ADIL Do?

Adial Pharmaceuticals, Inc., founded in 2010 and based in Charlottesville, Virginia, is a clinical-stage biopharmaceutical company dedicated to developing therapies for the treatment and prevention of addiction and related disorders. The company's primary focus is on addressing alcohol use disorder (AUD) through its lead product, AD04, a selective serotonin-3 antagonist. AD04 is currently in Phase III clinical trials, representing a significant milestone in its development. Beyond AD04, Adial Pharmaceuticals is also engaged in the discovery and development of drug candidates for non-opioid pain reduction and other diseases and disorders, expanding its potential therapeutic scope. The company operates within the competitive biotechnology landscape, striving to innovate and provide solutions for unmet medical needs in addiction treatment and pain management. Adial's commitment to research and development aims to create impactful therapies that improve patient outcomes and address critical healthcare challenges. The company's strategic focus on addiction and related disorders positions it within a growing market with substantial unmet needs, offering the potential for significant future growth and impact.

What Products and Services Does ADIL Offer?

• Develop therapeutics for the treatment of addiction.
• Focus on alcohol use disorder (AUD) treatment.
• Develop drug candidates for non-opioid pain reduction.
• Conduct Phase III clinical trials for AD04.
• Research and develop novel therapies for related disorders.
• Seek regulatory approval for their drug candidates.
• Potentially commercialize approved therapies.

How Does ADIL Make Money?

• Develop and patent novel drug candidates.
• Conduct clinical trials to demonstrate efficacy and safety.
• Seek regulatory approval from agencies like the FDA.
• Potentially commercialize approved drugs directly or through partnerships.

What Industry Does ADIL Operate In?

Adial Pharmaceuticals operates within the biotechnology industry, which is characterized by intense research and development, high regulatory scrutiny, and significant investment in innovative therapies. The market for addiction treatment is substantial, driven by the increasing prevalence of substance use disorders and the growing recognition of addiction as a chronic disease. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms focused on developing novel treatments. Adial's focus on AD04 positions it within a niche market for AUD treatments, where there is a need for more effective and targeted therapies.

Who Are ADIL's Key Customers?

• Patients suffering from alcohol use disorder (AUD).
• Healthcare providers who treat patients with AUD.
• Pharmacies and hospitals that dispense AUD medications.
• Potential pharmaceutical partners for licensing or co-development agreements.

Company Profile

Adial Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Glen Allen, US. The company is led by CEO Cary John Claiborne. ADIL has traded publicly since 2018.

Adial Pharmaceuticals, Inc. Financial Trajectory

Adial Pharmaceuticals, Inc. (ADIL) reported $0 in revenue for Q2 FY2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $52.0M, with diluted EPS of $-11.25. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, ADIL averaged $-4.14 in diluted EPS.

How Adial Pharmaceuticals, Inc. Is Valued

Analyst price targets span from $6.00 to $11.00, with a consensus of $8.50. At the current price of $6.00, that implies approximately 42% upside potential. Relative to its peer group, ADIL's quantitative score of 33/100 is below the peer average of 88/100.

Adial Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.39 places it in the distress zone, a signal of elevated financial risk.

Adial Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 98.4% below estimates on average.

Over the past six months, Adial Pharmaceuticals, Inc. insiders filed 18 SEC Form 4 transactions — 0 sales and 18 purchases. On net that is roughly 718K shares acquired (about $793K) — insiders putting money in tends to read as conviction.

ADIL Financials

ADIL Latest News

ADIL Analyst Consensus

ADIL MoonshotScore

ADIL Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources